Trial Profile
A Randomized, Double-Blind, Placebo-Controlled Trial to Assess Safety and Tolerability During Treatment of Type 2 Diabetes (T2DM) With Usual Diabetes Therapy (UDT) and Either Cycloset or Placebo.
Status:
Completed
Phase of Trial:
Phase III
Latest Information Update: 10 Nov 2021
Price :
$35
*
At a glance
- Drugs Bromocriptine (Primary)
- Indications Type 2 diabetes mellitus
- Focus Adverse reactions; Registrational
- Acronyms CST
- Sponsors VeroScience
- 15 Jun 2015 Results published in the Journal of Diabetes Research, according to a VeroScience media release.
- 23 Jan 2013 Efficacy results from a subgroup of patients with poorly controlled type 2 diabetes have been reported in a Santarus and VeroScience media release. Results were also published in Endocrine Practice.
- 28 Oct 2011 Actual initiation date changed from Dec 2006 to Jan 2007 as reported by ClinicalTrials.gov.